PrP turnover in vivo and the time to effect of prion disease therapeutics.
Saved in:
| Title: | PrP turnover in vivo and the time to effect of prion disease therapeutics. |
|---|---|
| Authors: | Corridon TL; Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., O'Moore J; Weissman Hood Institute, Great Falls, Montana, United States of America., Seerley A; Weissman Hood Institute, Great Falls, Montana, United States of America., Sprague DA; Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Lian Y; Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Laversenne V; Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Noble B; Ionis Pharmaceuticals, Carlsbad, California, United States of America., Kamath NG; Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Serack FE; Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Shaikh AB; Charles River Laboratories, Worcester, Massachusetts, United States of America., Erickson B; IQ Proteomics, Framingham, Massachusetts, United States of America., Braun C; IQ Proteomics, Framingham, Massachusetts, United States of America., DeSouza-Lenz K; Comparative Medicine, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Howard M; Comparative Medicine, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Chan N; Comparative Medicine, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Jackson WS; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden., Reidenbach AG; Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America., Cabin DE; Weissman Hood Institute, Great Falls, Montana, United States of America., Vallabh SM; Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.; McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.; Department of Neurology, Harvard Medical School, Boston, Massachusetts, United States of America.; Prion Alliance, Cambridge, Massachusetts, United States of America., Grindeland Panter A; Weissman Hood Institute, Great Falls, Montana, United States of America., Oberbeck N; Gate Bio, Brisbane, California, United States of America., Zhao HT; Ionis Pharmaceuticals, Carlsbad, California, United States of America., Minikel EV; Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.; McCance Center for Brain Health and Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, United States of America.; Department of Neurology, Harvard Medical School, Boston, Massachusetts, United States of America.; Prion Alliance, Cambridge, Massachusetts, United States of America. |
| Source: | PLoS pathogens [PLoS Pathog] 2026 May 26; Vol. 22 (5), pp. e1014263. Date of Electronic Publication: 2026 May 26 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
